With ad­u­canum­ab caught on a cliff, Bio­gen’s Michel Vounatsos bets bil­lions on an­oth­er high-risk neu­ro play

With its FDA pitch on the Alzheimer’s drug ad­u­canum­ab hang­ing per­ilous­ly close to dis­as­ter, Bio­gen is rolling the dice on a $3.1 bil­lion deal that brings in com­mer­cial rights to one of the oth­er spot­light neu­ro drugs in late-stage de­vel­op­ment — af­ter it al­ready failed its first Phase III.

The big biotech has turned to Sage Ther­a­peu­tics for its lat­est deal, close to a year af­ter the crush­ing fail­ure of Sage-217, now dubbed zu­ra­nolone, in the MOUN­TAIN study.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN